The history of copyright's flagship drug presents a nuanced case for stakeholders in the pharmaceutical sector. While initially a tremendous success, producing billions, the exclusivity expiration and the subsequent entry of generic versions have drastically changed income. This poses questions about the ongoing sustainability of related drug proje